136 related articles for article (PubMed ID: 21903322)
1. Cytotoxicity of troglitazone through PPARγ-independent pathway and p38 MAPK pathway in renal cell carcinoma.
Fujita M; Yagami T; Fujio M; Tohji C; Takase K; Yamamoto Y; Sawada K; Yamamori M; Okamura N
Cancer Lett; 2011 Dec; 312(2):219-27. PubMed ID: 21903322
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
3. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of 15-deoxy-Δ(12,14)-prostaglandin J(2) through PPARγ-independent pathway and the involvement of the JNK and Akt pathway in renal cell carcinoma.
Fujita M; Tohji C; Honda Y; Yamamoto Y; Nakamura T; Yagami T; Yamamori M; Okamura N
Int J Med Sci; 2012; 9(7):555-66. PubMed ID: 22991494
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells.
Li M; Lee TW; Yim AP; Mok TS; Chen GG
J Cell Physiol; 2006 Nov; 209(2):428-38. PubMed ID: 16883598
[TBL] [Abstract][Full Text] [Related]
6. Troglitazone attenuates epidermal growth factor receptor signaling independently of peroxisome proliferator-activated receptor in PC-3 cells.
Zhu H; Pan X; Qi H; Wang X; Hou S; Han B; Liu Z; Xu L
Oncol Rep; 2011 Jan; 25(1):81-90. PubMed ID: 21109961
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer.
Fujita M; Hasegawa A; Yamamori M; Okamura N
J Exp Clin Cancer Res; 2017 Jul; 36(1):91. PubMed ID: 28673319
[TBL] [Abstract][Full Text] [Related]
8. Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
Takenokuchi M; Saigo K; Nakamachi Y; Kawano S; Hashimoto M; Fujioka T; Koizumi T; Tatsumi E; Kumagai S
Acta Haematol; 2006; 116(1):30-40. PubMed ID: 16809887
[TBL] [Abstract][Full Text] [Related]
9. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
[TBL] [Abstract][Full Text] [Related]
10. Cytoprotective effect of tauroursodeoxycholate on hepatocyte apoptosis induced by peroxisome proliferator-activated receptor gamma ligand.
Nonaka M; Tazuma S; Hyogo H; Kanno K; Chayama K
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e198-206. PubMed ID: 17868335
[TBL] [Abstract][Full Text] [Related]
11. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth.
Li M; Lee TW; Mok TS; Warner TD; Yim AP; Chen GG
J Cell Biochem; 2005 Nov; 96(4):760-74. PubMed ID: 16149072
[TBL] [Abstract][Full Text] [Related]
12. New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines.
Colin C; Salamone S; Grillier-Vuissoz I; Boisbrun M; Kuntz S; Lecomte J; Chapleur Y; Flament S
Breast Cancer Res Treat; 2010 Nov; 124(1):101-10. PubMed ID: 20054646
[TBL] [Abstract][Full Text] [Related]
13. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
Lecomte J; Flament S; Salamone S; Boisbrun M; Mazerbourg S; Chapleur Y; Grillier-Vuissoz I
Breast Cancer Res Treat; 2008 Dec; 112(3):437-51. PubMed ID: 18204896
[TBL] [Abstract][Full Text] [Related]
14. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
15. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells.
Motomura W; Okumura T; Takahashi N; Obara T; Kohgo Y
Cancer Res; 2000 Oct; 60(19):5558-64. PubMed ID: 11034103
[TBL] [Abstract][Full Text] [Related]
16. Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma.
Yuan J; Takahashi A; Masumori N; Uchida K; Hisasue S; Kitamura H; Itoh N; Tsukamoto T
Urology; 2005 Mar; 65(3):594-9. PubMed ID: 15780399
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
[TBL] [Abstract][Full Text] [Related]
18. EGR1 expression: a calcium and ERK1/2 mediated PPARγ-independent event involved in the antiproliferative effect of 15-deoxy-Δ12,14-prostaglandin J2 and thiazolidinediones in breast cancer cells.
Chbicheb S; Yao X; Rodeau JL; Salamone S; Boisbrun M; Thiel G; Spohn D; Grillier-Vuissoz I; Chapleur Y; Flament S; Mazerbourg S
Biochem Pharmacol; 2011 May; 81(9):1087-97. PubMed ID: 21338579
[TBL] [Abstract][Full Text] [Related]
19. The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells.
Yan KH; Yao CJ; Chang HY; Lai GM; Cheng AL; Chuang SE
Mol Carcinog; 2010 Mar; 49(3):235-46. PubMed ID: 19908241
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of ERK activity enhances the cytotoxic effect of peroxisome proliferator-activated receptor γ (PPARγ) agonists in HeLa cells.
Chang HK; Kim DS; Chae JJ; Kim M; Myong JP; Lee KH; Lee MW; Park TC
Biochem Biophys Res Commun; 2017 Jan; 482(4):843-848. PubMed ID: 27888104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
